ETC-216 for coronary artery disease

Bibliography

• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-89
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (Lipid) study group. N Engl J Med 1998;339:1349-57
   PubMed Web of Science ®Google Scholar
• MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFcaps/Texcaps. AirForce/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Rifkind BM. High-density lipoprotein--the clinical implications of recent studies. N Engl J Med. 1989;321:1311-16
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977;62:707-14
   PubMed Web of Science ®Google Scholar
• Badimon JJ, Badimon L, Galvez A, High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 1989;60:455-61
   PubMed Web of Science ®Google Scholar
• Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990;85:1234-41
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Cutri B, Worthley SG, Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 2005;25:2416-21
   PubMed Web of Science ®Google Scholar
• Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Nat Acad Sci USA 1994;91:9607-11
   PubMed Web of Science ®Google Scholar
• Rubin EM, Krauss RM, Spangler EA, Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991;353:265-7
   PubMed Web of Science ®Google Scholar
• Rong JX, Li J, Reis ED, Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001;104:2447-52
   PubMed Web of Science ®Google Scholar
• Shah PK, Yano J, Reyes O, High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Circulation 2001;103:3047-50
   PubMed Web of Science ®Google Scholar
• Brewer HB Jr. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr Cardiol Rep 2007;9:486-92
   PubMedGoogle Scholar
• Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010;30:139-143
   PubMed Web of Science ®Google Scholar
• Barter PJ, Nicholls S, Rye KA, Antiinflammatory properties of HDL. Circ Res 2004;95:764-72
   PubMed Web of Science ®Google Scholar
• Shaul PW, Mineo C. HDL action on the vascular wall: is the answer NO? J Clin Invest 2004;113:509-13
   PubMed Web of Science ®Google Scholar
• Bisoendial RJ, Hovingh GK, Levels JHM, Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003;107:2944-8
   PubMed Web of Science ®Google Scholar
• Spieker LE, Sudano I, Hurlimann D, High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002;105:1399-402
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Dusting GJ, Cutri B, Reconstituted high density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005;111:1543-50
   PubMed Web of Science ®Google Scholar
• Kraus WE, Houmard JA, Duscha BD, Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002;347:1483-92
   PubMed Web of Science ®Google Scholar
• Cui Y, Watson DJ, Girman CJ, Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol 2009;104:829-34
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2004;20:627-37
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I, Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007;297:499-508
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84
   PubMed Web of Science ®Google Scholar
• Robins SJ, Collins D, Wittes JT, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91
   PubMed Web of Science ®Google Scholar
• Otvos JD, Collins D, Freedman DS, Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation 2006;113:1556-63
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao X-Q, Chait A, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ, Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK, Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Calabresi L, Franceschini G, Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001;103:1949-54
   PubMed Web of Science ®Google Scholar
• Calabresi L, Sirtori CR, Paoletti R, Franceschini G. Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases. Curr Atheroscler Rep 2006;8:163-7
   PubMedGoogle Scholar
• Ameli S, Hultgardh-Nilsson A, Cercek B, Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994;90:1935-41
   PubMed Web of Science ®Google Scholar
• Soma MR, Donetti E, Parolini C, Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ Res 1995;76:405-11
   PubMed Web of Science ®Google Scholar
• Kaul S, Rukshin V, Santos R, Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation 2003;107:2551-4
   PubMed Web of Science ®Google Scholar
• Shah PK, Nilsson J, Kaul S, Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 1998;97:780-5
   PubMed Web of Science ®Google Scholar
• Kaul S, Coin B, Hedayiti A, Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J Am Coll Cardiol 2004;44:1311-19
   PubMed Web of Science ®Google Scholar
• Chiesa G, Monteggia E, Marchesi M, Recombinant Apolipoprotein A-IMilano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002;90:974-80
   PubMed Web of Science ®Google Scholar
• Parolini C, Marchesi M, Lorenzon P, Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol 2008;51:1098-103
   PubMed Web of Science ®Google Scholar
• Ibanez B, Vilahur G, Cimmino G, Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol 2008;51:1104-9
   PubMed Web of Science ®Google Scholar
• Ibanez B, Cimmino G, Benezet-Mazuecos J, Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. Atherosclerosis 2009;202:185-91
   PubMed Web of Science ®Google Scholar
• Marchesi M, Booth EA, Rossoni G, Apolipoprotein A-IMilano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart. Atherosclerosis 2008;197:572-8
   Google Scholar
• Marchesi M, Booth EA, Davis T, Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury. J Pharmacol Exp Ther 2004;311:1023-31
   PubMed Web of Science ®Google Scholar
• Speidl WS, Cimmino G, Ibanez B, Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur Heart J 2010;31:2049-57
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-300
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hsu A, Wolski K, Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010;55:2399-2407
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I, Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006;47:992-7
   PubMed Web of Science ®Google Scholar
• Weibel GL, Alexander ET, Joshi MR, Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Arterioscler Thromb Vasc Biol 2007;27:2022-9
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L'Allier PL, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675-82
   PubMed Web of Science ®Google Scholar
• Waksman R, Torguson R, Kent KM, A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010;55:2727-35
   PubMed Web of Science ®Google Scholar
• Bailey D, Jahagirdar R, Gordon A, RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 2010;55:2580-89
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Ballantyne CM, Kastelein JJ, Results of the first major clinical trial of an oral agent inducing apoA1 synthesis: a new approach to HDL raising and CV risk modification. Circulation 2010;122:2220
   Web of Science ®Google Scholar
• Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev 2010;18:141-7
   PubMed Web of Science ®Google Scholar
• Barter PJ. Hugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors. Atheroscler Suppl 2002;3:39-47
   PubMed Web of Science ®Google Scholar
• Barter PJ. CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2029-31
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW, Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L, Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
   PubMed Web of Science ®Google Scholar
• Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol 2009;104:32E-38E
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15
   PubMed Web of Science ®Google Scholar
• Badellino KO, Wolfe ML, Reilly MP, Rader DJ. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med 2006;3:e22
   PubMed Web of Science ®Google Scholar
• Cavender MA, Nicholls SJ, Lincoff AM. Strategies for the development of new PPAR agonists in diabetes. Eur J Cardiovasc Prev Rehabil 2010;17(Suppl 1):S32-37
   PubMedGoogle Scholar
• Li AC, Glass CK. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 2004;45:2161-73
   PubMed Web of Science ®Google Scholar
• Ansell BJ, Navab M, Hama S, Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751-6
   PubMed Web of Science ®Google Scholar
• Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006;58:342-74
   PubMed Web of Science ®Google Scholar
• Zheng L, Nukuna B, Brennan ML, Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-41
   PubMed Web of Science ®Google Scholar
• Wang Z, Nicholls SJ, Rodriguez ER, Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007;13(10):1176-84
   Google Scholar
• Vaisar T, Pennathur S, Green PS, Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-56
   PubMed Web of Science ®Google Scholar
• Bhattacharyya T, Nicholls SJ, Topol EJ, Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76
   PubMed Web of Science ®Google Scholar